Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

12 Nov
British National Formulary logo
BNF November 2019 Update

This update contains 11 significant changes, 2 dose changes and 7 new preparations. 

Significant Changes:  

  • Benralizumabfor treating severe eosinophilic asthma (updated advice) [NICE guidance]. 
  • Fingolimod (Gilenya®): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception [MHRA/CHM advice].
  • Hormone replacement therapy (HRT) (conjugated oestrogens (equine) and estradiol): further information on the known increased risk of breast cancer with HRT and its persistence after stopping [MHRA/CHM advice]. 
  • Human papillomavirus vaccine updated guidance in-line with Public Health England recommendations.
  • Hypertension: updated guidance on management of hypertension in pregnancy.
  • Immunisation schedule: updated national human papillomavirus immunisation programme in-line with Public Health England recommendations.
  • Mitomycin (Mitomycin-C Kyowa® 40 mg): restricted to intravesical administration only for treatment of superficial bladder cancer [MHRA/CHM advice].
  • Montelukast (Singulair®): reminder of the risk of neuropsychiatric reactions [MHRA/CHM advice].
  • Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer [NICE guidance].
  • Pentosan polysulfatesodium (Elmiron®): rare risk of pigmentary maculopathy [MHRA/CHM advice]. 
  • Sodium zirconium cyclosilicate for treating hyperkalaemia [NICE guidance].
     

Dose Changes:  

  • Magnesium sulfate: Change to additional dose for seizure recurrence in pre-eclampsia and eclampsia.
  • Human papillomavirus vaccines: Dosing now includes male patients.

 

New Preparations:  
Dupixent® [dupilumab], Gardasil 9® [human papillomavirus vaccines], Lorviqua® [lorlatinib], Nyxoid® [naloxone hydrochloride], Talzenna® [talazoparib], Vitrakvi® [larotrectinib], Waylivra® [volanesorsen]. 

 

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm 

 

12 Nov
Stockleys Drug Interactions_logo
Stockley’s Drug Interactions November 2019 Update

Stockley’s Drug Interactions update with new and revised monographs.

For this update, the monographs on the anti-androgens have been completely re-validated and updated, and apalutamide has been added. There are 7 new monographs and 31 existing monographs have been updated.

12 Nov
Pharmaceutical Excipients logo
Pharmaceutical Excipients November 2019 Update

This update contains 34 updated monographs, 4 new spectral images and an initial revalidation of the Suppliers Directory. The European Pharmacopoeia, and USP-NF information has been globally updated. 

Revised monographs: Ascorbic Acid; Bentonite; Benzyl Alcohol; Colophony; Crospovidone; Dextran; Dibutyl Sebacate; Diethyl Sebacate; Fructose; Fumaric Acid; Gelatin; Hydroxyethyl-β-cyclodextrin; Kaolin; Lactitol; Mannitol and Sorbitol; d-Mannose; Mineral Oil and Lanolin Alcohols; Oleyl Alcohol; Poloxamer; Polymethacrylates; Polyoxyl 15 Hydroxystearate; Potassium Hydroxide; Povidone; Sodium Lactate; Sodium Thiosulfate; Squalane; Starch, Sterilizable Maize; Sucrose Stearate; Talc; Trimethyl-β-cyclodextrin; Wax, Microcrystalline; Wax, White; Wax, Yellow; Xanthan Gum. 

Minor Updates: New SEMs for Poloxamer.

12 Nov
Stockley's Interactions Checker_logo
Stockley’s Interaction Checker November 2019 Update

New and updated interactions now available.

For November, 603 new interactions have been added and 368 existing interactions have been updated.

12 Nov
British National Formulary for Children logo
BNF for Children November 2019 Update

This update contains 5 significant changes, 1 dose change and 5 new preparations. 

Significant Changes:  

  • Fingolimod (Gilenya®): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception [MHRA/CHM advice]. 
  • Human papillomavirus vaccine updated guidance in-line with Public Health England recommendations. 
  • Immunisation schedule: updated national human papillomavirus immunisation programme in-line with Public Health England recommendations. 
  • Montelukast (Singulair®): reminder of the risk of neuropsychiatric reactions [MHRA/CHM advice]. 
  • Parenteral nutrition supplements: light protection required to reduce the risk of serious adverse effects in premature neonates [MHRA/CHM advice]. 

Dose Changes:  

  • Human papillomavirus vaccines: Dosing now includes male patients. 

New Preparations:  
Dupixent® [dupilumab], Gardasil 9® [human papillomavirus vaccines], Nyxoid® [naloxone hydrochloride], Orkambi® granules [lumacaftor with ivacaftor], Vitrakvi® [larotrectinib]. 

 
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes 

12 Nov
AHFS Drug Information logo
AHFS November 2019 Update

This update contains 7 new monographs, 35 revised monographs, 2 discontinued monographs and 2 new MedWatch alerts.

New monographs: Darolutamide; Pexidartinib; Upadacitinib.

Revised monographs: Moxifloxacin; Entacapone; valGANciclovir; Tegaserod; Denosumab; Tofacitinib; Baricitinib; Cemiplimab-rwlc; Baloxavir; Nitroglycerin; Preface to Penicillins; Ganciclovir; Foscarnet; Cidofovir; levoFLOXacin.

Discontinued monographs:  

Extended-spectrum penicillins GS; Cardiac glycosides GS. 

New MedWatch alerts on the following monographs:  

Elbasvir and Grazoprevir; Sofosbuvir, Velpatasvir, and Voxilaprevir; Glecaprevir and Pibrentasvir; Palbociclib; Ribociclib; Abemaciclib. 

View more